About: 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1987

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1987 (uk) article scientifique publié en 1987 (fr) im Juni 1987 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1987 (ast) scientific article published on 01 June 1987 (en)
publication date	wds:Q69899893-71BEBD49-1234-4F32-8C64-80B4DEB378F5
publication date	1987-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q69899893-2163C217-DC86-495A-9C30-E200C49D84A1
language of work or name	English
cites work	wds:Q69899893-33B8D9CA-055A-4077-A82A-BA21E6D8D3F8 wds:Q69899893-A69E9CF5-9280-4218-99D1-B62CE78F7CC5 wds:Q69899893-A87FAD8C-8144-44C0-9A38-E897ABA89B3D wds:Q69899893-ABFE757E-9857-435F-A0CD-3BCBE48E0323 wds:Q69899893-B02198E1-7E1C-46F5-920E-73DE99554057 wds:Q69899893-C471154D-4C89-4C0E-9D1B-42BA4D439143 wds:Q69899893-C64F1BDD-CB81-41E5-B8B8-F87A6D95710A
cites work	Dose response studies using desferrioxamine and orally active chelators in a mouse model New orally active iron chelators Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Iron chelation with oral desferrioxamine Desferrioxamine suppositories Clinical management of thalassemia. The status of new iron chelators
author name string	wds:Q69899893-403214D3-2822-471F-8B03-9C605EEAABA6 wds:Q69899893-A754E973-2F76-4B50-9029-C8A9B6BDEFD2 wds:Q69899893-AE95DAB7-160A-4BED-9317-5391A4863306 wds:Q69899893-DF131659-9D5C-4EDB-8F3C-32E536FAF87C
author name string	A V Hoffbrand G J Kontoghiorghes L Sheppard M A Aldouri
rdfs:label	1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (en) 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (nl)
skos:prefLabel	1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (en) 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (nl)
name	1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (en) 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (nl)
title	wds:Q69899893-63167053-8EAE-4F52-9F3E-7C87FA2AA659
title	1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload (en)
page(s)	wds:Q69899893-BED229D9-D08C-4A78-9C49-A0BF687ED517
page(s)	1294-1295
instance of	wds:Q69899893-5E221A9E-E8A1-4DE3-A630-99961C8EA6BF
instance of	scholarly article
main subject	wds:Q69899893-8A52B2F7-2DEF-49C8-B769-912B22335FB1
main subject	iron overload
PubMed ID	wds:Q69899893-82E2C83A-865F-4C40-A518-88839F251951
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2884415
PubMed ID	2884415
published in	wds:Q69899893-A9431CA8-A9E1-4E5D-A14F-34DB627EF1D2
published in	The Lancet
issue	wds:Q69899893-FC3FF8C8-54BE-4B59-9967-B93D0F188926
volume	wds:Q69899893-F4A5A555-B90A-4D45-ABB2-F8636AC4C895
issue	8545
volume	1
DOI	wds:Q69899893-A45448BE-3172-4897-918E-40007F70C733
DOI	http://dx.doi.org/10.1016/S0140-6736(87)90545-9
DOI	10.1016/S0140-6736(87)90545-9
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q69899893
is cites work of	Deferasirox for managing iron overload in people with thalassaemia Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases A risk-benefit assessment of iron-chelation therapy Inhibition of growth of Histoplasma capsulatum yeast cells in human macrophages by the iron chelator VUF 8514 and comparison of VUF 8514 with deferoxamine Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective Recent advances in β-thalassemias Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1). Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients Oral iron chelation with deferiprone A delicate balance: Iron metabolism and diseases of the brain. New trends in the treatment of beta-thalassemia Iron chelation therapy: the need for orally active drugs Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine Animal toxicology of iron chelator L1 Iron chelators as therapeutic agents against Pneumocystis carinii Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan The development of iron chelating drugs 2 Clinically Useful Chelators of Tripositive Elements Iron chelating drugs The involvement of lysosomes in myocardial aging and disease Deferasirox for managing transfusional iron overload in people with sickle cell disease Deferasirox for managing iron overload in people with thalassaemia Clinically useful chelators of tripositive elements. Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment Deferasirox for managing iron overload in people with thalassaemia Deferasirox for managing iron overload in patients with myelodysplastic syndrome Deferasirox for managing transfusional iron overload in people with sickle cell disease Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software